Astrocytes, the most abundant cells in the central nervous system (CNS), play diverse roles in the regulation of neuronal activity, vascular function and gliotransmitter release. In neurodegenerative diseases, pathologically activated astrocytes show astrogliosis, which is clinically characterized by an abnormal cell morphology and excessive astrocyte proliferation. Thrombin, a crucial factor for brain injury after intracerebral hemorrhage, activates astrocytic Ca 2＋ signaling through a speciˆc subtype of the thrombin receptor, termed the proteinase-activated receptor (PAR). In this study, we demonstrate a novel pathophysiological role for transient receptor potential canonical 3 (TRPC3) Ca 2＋ -permeable nonselective cation channels in thrombin-activated astrocytes. In 1321N1 human astrocytoma cells and cultured rat cortical astrocytes, thrombin induced heterogeneous Ca 2＋ responses with asynchronous repetitive peaks. These oscillations were found to be the result of repetitive Ca 2＋ release from intracellular stores followed by replenishment of the stores with Ca 2＋ from the extracellular region. The oscillations occurred without a direct [Ca 2＋ ] i increase and were inhibited by the selective TRPC3 inhibitor pyrazole-3. Pharmacological manipulation with BAPTA-AM, cyclopiazonic acid, 2-aminoethoxydiphenyl borate and pyrazole-3 indicated that Ca 2＋ mobilization through TRPC3 was involved in thrombin-induced changes in the morphology of astrocytes. Moreover, thrombin-induced upregulation of S100B, a marker of reactive astrocytes, at 20 h and increased astrocytic proliferation at 72 h were inhibited by Ca 2＋ signaling blockers and knockdown of TRPC3 with speciˆc siRNA. Taken together, these results suggest that TRPC3 may constitute a new therapeutic target for brain injury after intracerebral hemorrhage.
Thrombin was continuously applied for 3 h. Arrows indicate rounded cells. Scale bar shows 50 mm. C, Time-dependence of thrombin-induced cell rounding. After the exposure to thrombin at each time,ˆxed cells were examined by microscopy followed by the calculation of rounding rate. D, Reversibility of thrombin-induced cell rounding. Cells wereˆxed at each time after the appropriate application of thrombin. E, RT-PCR analysis for human TRPCs in the astrocytoma cells. F, EŠects of siRNA for TRPC3 on its endogenous expression in the astrocytoma cells. G, EŠects of TRPC3 siRNA on thrombin-induced cell rounding. (   p＜0.001 vs. control siRNA). H, EŠects of siRNA for TRPC3 on thrombin-induced repetitive Ca 2＋ responses (  p＜0.01 vs. scrambled siR-NA). I, Concentration-dependent eŠects of pyrazole-3 on thrombin-induced cell rounding (  p＜0.01,    p＜0.001 vs. thrombin alone). J, EŠects of a TRPC3 selective inhibitor pyrazole-3 at 10 mM on thrombin-induced repetitive Ca 2＋ responses (   p＜0.001 vs. thrombin alone).
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Vol. 132 (2012) Drugs were applied during the periods indicated by the horizontal bars. C E, Thrombin-induced alterations of TRPC expression in rat cortical astrocytes. C, RT-PCR analysis for TRPC1, TRPC3, TRPC6, and TRPC7 mRNA in cultured rat astrocytes. Rat brain mRNA was used as a positive control for TRPC3 and TRPC7. D, Quantitative RT-PCR analysis for TRPC1, TRPC3, and TRPC6 mRNA in serum-starved rat cortical astrocytes with or without application of 1 U/mL thrombin for 12 h ( p＜0.05 vs. control). E, Typical Western blot band for TRPC3 protein in serum-starved rat cortical astrocytes with or without application of 1 U/mL thrombin for 20 h (   p＜0.001 vs. control).
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Vol. Typical images (A) and summarized data (B) of serum-starved astrocytes transfected with a scrambled siRNA (upper) or TRPC3 siRNA (lower) and S100Bexpressing astrocytes treated with normal medium (left photos in A) or medium containing thrombin (1 U/mL; right photos in A) for 20 h. The signal intensity ratio was calculated by dividing the total S100B signal intensity by the total number of Hoechst-positive cells. C, EŠect of speciˆc knockdown of TRPC3 in thrombin-induced cell proliferation.   p＜0.01,    p＜0.001 vs. serum-free control (scrambled siRNA), ### p＜0.001 vs. serum-free control (TRPC3 siRNA). Cell proliferation was calculated as a percentage of control by setting the value of untreated cells to 0％ and the value of cells grown in EMEM containing 10％ FBS for 72 h to 100％ in an MTT assay. 
